<DOC>
	<DOCNO>NCT01595009</DOCNO>
	<brief_summary>To provide everolimus patient p-NET , GI lung NETs potential everolimus approval , expand access study CRAD001K24133 design provide treatment disease progression unacceptable toxicity 30 May 2012 , whichever occur first . In study , 60 patient GI lung NETs enrol Germany still approximately 40 patient benefit everolimus treatment . To provide study medication patient beyond 30 May 2012 , open label extension allow patient experience clinical benefit everolimus treatment suffer unacceptable toxicity continue receive treatment therapy disease progression , unacceptable toxicity , study end 31 May 2014 , whichever come first . Patients follow safety tolerability efficacy everolimus .</brief_summary>
	<brief_title>Extension Study Open-label , Multi-center , Expanded Access Study Everolimus Patients With Advanced Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion The patient must provide sign Informed Consent Form ( ICF ) extension study prior study related procedure Age â‰¥18 year old Completion whole treatment period CRAD001K24133 study Neuroendocrine tumor gastrointestinal pulmonary origin ( pancreatic neuroendocrine tumor exclude ) No tumor progression therapy everolimus CRAD001K24133 study ( checked via radiologically assessment ) No intolerable toxicity therapy everolimus , combination therapy everolimus somatostatin analogue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>